While there are some reports on the use and effects of insulin/IGF-targeting trials in colorectal cancer (reviewed in References [104,179]), there is not much published data regarding the effect of the CRC treatment using precise anti-IGF2 approaches. This evidence concerns the gene IGF1 and colorectal cancer.